Barclays’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$736M Sell
5,282,196
-3,833,287
-42% -$537M 0.18% 85
2025
Q4
$1.12B Buy
9,115,483
+3,942,335
+76% +$479M 0.27% 49
2025
Q3
$574M Sell
5,173,148
-923,527
-15% -$105M 0.12% 107
2025
Q2
$676M Buy
6,096,675
+492,410
+9% +$52.4M 0.15% 82
2025
Q1
$628M Buy
5,604,265
+1,204,178
+27% +$124M 0.18% 81
2024
Q4
$406M Buy
4,400,087
+171,289
+4% +$15.4M 0.11% 115
2024
Q3
$355M Sell
4,228,798
-427,594
-9% -$32.6M 0.09% 151
2024
Q2
$319M Sell
4,656,392
-2,151,007
-32% -$144M 0.1% 157
2024
Q1
$499M Buy
6,807,399
+1,127,429
+20% +$86.7M 0.17% 103
2023
Q4
$460M Buy
5,679,970
+1,859,883
+49% +$145M 0.17% 99
2023
Q3
$286M Sell
3,820,087
-2,822,823
-42% -$217M 0.18% 118
2023
Q2
$512M Buy
6,642,910
+2,126,182
+47% +$170M 0.32% 59
2023
Q1
$375M Sell
4,516,728
-1,470,740
-25% -$122M 0.17% 68
2022
Q4
$514M Buy
5,987,468
+4,138,589
+224% +$328M 0.23% 59
2022
Q3
$114M Sell
1,848,879
-293,188
-14% -$18.5M 0.12% 160
2022
Q2
$132M Sell
2,142,067
-778,053
-27% -$48.2M 0.08% 183
2022
Q1
$174M Sell
2,920,120
-2,440,498
-46% -$156M 0.14% 154
2021
Q4
$389M Buy
5,360,618
+2,272,720
+74% +$157M 0.15% 118
2021
Q3
$216M Buy
3,087,898
+396,577
+15% +$27.9M 0.1% 169
2021
Q2
$185M Buy
2,691,321
+44,088
+2% +$2.94M 0.09% 184
2021
Q1
$171M Buy
2,647,233
+792,952
+43% +$51.1M 0.09% 177
2020
Q4
$108M Buy
1,854,281
+416,094
+29% +$25.1M 0.06% 253
2020
Q3
$90.9M Buy
1,438,187
+305,188
+27% +$21.2M 0.05% 256
2020
Q2
$87.2M Sell
1,132,999
-1,283,828
-53% -$98.4M 0.07% 217
2020
Q1
$181M Sell
2,416,827
-497,581
-17% -$34.4M 0.14% 97
2019
Q4
$189M Sell
2,914,408
-930,759
-24% -$60.6M 0.11% 153
2019
Q3
$244M Buy
3,845,167
+1,062,999
+38% +$69.5M 0.15% 104
2019
Q2
$188M Buy
2,782,168
+165,238
+6% +$10.9M 0.12% 141
2019
Q1
$170M Buy
2,616,930
+21,421
+0.8% +$1.42M 0.12% 136
2018
Q4
$162M Buy
2,595,509
+414,108
+19% +$28.9M 0.13% 114
2018
Q3
$168M Sell
2,181,401
-95,433
-4% -$7.21M 0.12% 127
2018
Q2
$161M Sell
2,276,834
-668,208
-23% -$47.2M 0.14% 116
2018
Q1
$222M Buy
2,945,042
+208,297
+8% +$16.6M 0.17% 98
2017
Q4
$196M Buy
2,736,745
+713,552
+35% +$54.2M 0.16% 112
2017
Q3
$164M Sell
2,023,193
-3,216,284
-61% -$246M 0.17% 95
2017
Q2
$371M Buy
5,239,477
+775,798
+17% +$51.6M 0.4% 30
2017
Q1
$303M Buy
4,463,679
+9,007
+0.2% +$633K 0.33% 38
2016
Q4
$319M Buy
4,454,672
+986,353
+28% +$73.3M 0.34% 31
2016
Q3
$274M Buy
3,468,319
+2,014,666
+139% +$164M 0.3% 41
2016
Q2
$121M Sell
1,453,653
-2,778,798
-66% -$247M 0.16% 102
2016
Q1
$385M Buy
4,232,451
+2,654,236
+168% +$239M 0.59% 18
2015
Q4
$159M Sell
1,578,215
-633,576
-29% -$65.9M 0.19% 87
2015
Q3
$217M Sell
2,211,791
-40,600
-2% -$4.51M 0.26% 52
2015
Q2
$264M Sell
2,252,391
-573,080
-20% -$62.6M 0.3% 35
2015
Q1
$277M Sell
2,825,471
-490,512
-15% -$49.8M 0.32% 36
2014
Q4
$312M Sell
3,315,983
-251,624
-7% -$26M 0.3% 44
2014
Q3
$378M Buy
3,567,607
+1,867,671
+110% +$183M 0.36% 32
2014
Q2
$139M Sell
1,699,936
-3,024,086
-64% -$235M 0.15% 92
2014
Q1
$331M Buy
4,724,022
+3,082,462
+188% +$242M 0.37% 37
2013
Q4
$123M Buy
1,641,560
+244,354
+17% +$17M 0.13% 120
2013
Q3
$86.6M Buy
1,397,206
+253,079
+22% +$15.1M 0.1% 154
2013
Q2
$58.7M Buy
+1,144,127
New +$59.6M 0.07% 220

Other funds holding GILD

Barclays's GILD Position: Q1 2026 in Review

Barclays reduced its Gilead Sciences (GILD) stake by 42% in Q1 2026, selling an estimated $537M and leaving 5,282,196 shares worth $736M. The position accounts for 0.18% of the portfolio, ranked #85.

Barclays first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.12B in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Barclays held 5,282,196 shares of Gilead Sciences worth $736M as of Q1 2026.
  • Barclays sold 3,833,287 Gilead Sciences shares in Q1 2026, an estimated $537M.
  • Gilead Sciences made up 0.18% of Barclays's portfolio in Q1 2026, its #85 holding.
  • Barclays first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Gilead Sciences position peaked at $1.12B in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.